Examples
|
| Copaxone | glatiramer acetate | |
How It Works
Glatiramer acetate (formerly known as
copolymer-1) is an artificial
protein that resembles a natural myelin protein. It is
not known exactly how the medication works, but it may help people who have
multiple sclerosis (MS) by preventing the body's
immune system from attacking the myelin coating that
protects nerve fibers.
Glatiramer acetate is given as an injection
beneath the skin one time a day. An oral tablet form has been tested but failed
to show any benefit for people with MS.
Why It Is Used
Glatiramer acetate may be used to
treat people 18 years or older who have
relapsing-remitting MS. It is not approved to treat
other forms of MS.
How Well It Works
Glatiramer acetate significantly
reduces the frequency of
relapses in those with relapsing-remitting MS. It also
slows the number of new lesions (tissue damage) as seen on MRI and decreases
disability.1
Glatiramer acetate can slow
the rate of new lesions in those with relapsing-remitting MS, without the
flu-like symptoms that interferon beta medications can cause.1
Glatiramer acetate has not been shown to be
effective for people who have
secondary progressive MS. Also, the medication is not
helpful for people who have
primary progressive MS.
Side Effects
Some people may have temporary side
effects right after the shot (post-injection reaction), which can
include:
- Pain, redness, or swelling at the injection
site.
- Flushing.
- Chest pain, rapid heartbeat, and
shortness of breath similar to that experienced in a
heart attack.
- Anxiety.
- Tightness in the throat.
These side effects are usually mild and go away on their
own shortly after the injection. You may have one or several brief episodes of
these side effects during your treatment with glatiramer acetate.
Although less common, other side effects may occur, including:
- Weakness.
- Nausea.
- Joint
pain.
- Severe muscle tension or spasticity.
- Skin
rash.
- Impotence or decreased interest in sex.
See Drug Reference for a full list of side effects. (Drug
Reference is not available in all systems.)
What To Think About
Treatment with glatiramer
acetate should not be started until it is clear that you have the
relapsing-remitting form of MS. The National Multiple Sclerosis Society
recommends that treatment with glatiramer acetate or one of the interferon
medications be started as soon as a clear diagnosis is made.2
The safety of glatiramer acetate during
pregnancy and breast-feeding is not known. Talk to your doctor if you are
planning a pregnancy, if you are pregnant, or if you are breast-feeding.
In addition to side effects, there are some drawbacks to treatment with
glatiramer acetate:
- Treatment is not effective at all for some
people, and it is hard to predict whether the medication will help a particular
person.
- The long-term risks of treatment are unknown. It is
possible that long-term use of the medication may lower the body's defense
against other diseases. For people with mild MS, the benefits may not be worth
the possible risks.
- Treatment may cost
more than $15,000 per year.
If you are taking glatiramer acetate, do not stop taking it
without first talking with your doctor.
Complete the new medication information form (PDF)
(What is a PDF document?)
to help you understand this medication.
References
Citations
Simpson D, et al. (2003). Spotlight on glatiramer
acetate in relapsing-remitting multiple sclerosis. Biodrugs, 17(3): 207-210.
National Clinical Advisory Board of the National
Multiple Sclerosis Society (2007). Disease Management Consensus Statement. New York: National Multiple Sclerosis Society. Available
online:
http://www.nationalmssociety.org/site/PageServer?pagename=HOM_PRO_expert_opinion_papers.
Credits
| Author | Monica Rhodes |
| Editor | Kathleen M. Ariss, MS |
| Associate Editor | Denele Ivins |
| Associate Editor | Pat Truman, MATC |
| Primary Medical Reviewer | Anne C. Poinier, MD - Internal Medicine |
| Specialist Medical Reviewer | Colin Chalk, MD, CM, FRCPC - Neurology |
| Last Updated | February 28, 2008 |
Simpson D, et al. (2003). Spotlight on glatiramer
acetate in relapsing-remitting multiple sclerosis. Biodrugs, 17(3): 207-210.
National Clinical Advisory Board of the National
Multiple Sclerosis Society (2007). Disease Management Consensus Statement. New York: National Multiple Sclerosis Society. Available
online:
http://www.nationalmssociety.org/site/PageServer?pagename=HOM_PRO_expert_opinion_papers.